[1]
Iannazzo, S. et al. 2016. [Cost-effectiveness analysis of peginterferon beta-1a in Italian relapsing remitting multiple sclerosis management]. Farmeconomia. Health economics and therapeutic pathways. 17, 2S (Jul. 2016), 13–36. DOI:https://doi.org/10.7175/fe.v17i2S.1230.